erlotinib hydrochloride has been researched along with Angiogenesis, Pathologic in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (33.33) | 29.6817 |
| 2010's | 23 (63.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, C; Hara, N; Higo, H; Hirabae, A; Hotta, K; Ichihara, E; Kano, H; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Nakasuka, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Okawa, S; Rai, K; Tabata, M; Watanabe, H | 1 |
| Camorani, S; Cerchia, L; Crescenzi, E; Fedele, M; Gramanzini, M; Zannetti, A | 1 |
| Aikawa, H; Hamada, A; Hayashi, M; Kawanishi, T; Masuda, C; Nishidate, M; Yamamoto, K | 1 |
| Li, W; Zhou, Y | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY | 1 |
| Fujii, T; Fujiwara, M; Fukuda, S; Hotta, Y; Kanda, M; Kasuya, H; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Nomoto, S; Sahin, TT; Sugimoto, H; Tan, G; Tanaka, C; Tanaka, M; Tsurumaru, N; Yamada, S; Yamamura, K | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L | 1 |
| Lee, JG; Wu, R | 1 |
| Baty, F; Betticher, D; Brutsche, MH; Droege, C; Dürr, O; Franzini, A; Grigoriu, BD; Klingbiel, D; Macovei, II; Zappa, F | 1 |
| Cascone, T; Heymach, JV | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Jing, DD; Lu, YY; Wang, XP; Wu, K; Xu, M | 1 |
| Angagaw, MH; Bettano, KA; Chenard, M; Haines, BB; Reilly, JF; Sevilla, RS; Sur, C; Tong, C; Ware, C; Winkelmann, CT; Zhang, W | 1 |
| Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL | 1 |
| Finn, RS; Zhu, AX | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Lam, KC; Mok, TS | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT | 1 |
| Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H | 1 |
| Akama-Garren, EH; Edalati, A; Lindstrom, TM; Petralia, JD; Robinson, WH; Ruiz, PJ; Stein, EA; Swanson, CD | 1 |
| Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W | 1 |
| Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S | 1 |
| Abou-Alfa, GK; Ang, C; O'Reilly, EM | 1 |
| Anand-Apte, B; Blobel, CP; Chan, RV; Chiang, MF; Farage, E; Glomski, K; Hewing, NJ; Khokha, R; Swendeman, S; Vermaat, J; Weskamp, G | 1 |
| Bozec, A; Fischel, JL; Milano, G | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Collins, MH; Cripe, TP; Crombleholme, TM; Currier, MA; Hsu, YH; Mahller, YY; Mehrian-Shai, R; Miller, SJ; Ratner, N; Ripberger, MC; Vaikunth, SS | 1 |
| Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X | 1 |
| Giordano, S; Petrelli, A | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
14 review(s) available for erlotinib hydrochloride and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
[Dose finding methods for targeted agents: new perspectives].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neovascularization, Pathologic; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
1 trial(s) available for erlotinib hydrochloride and Angiogenesis, Pathologic
| Article | Year |
|---|---|
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
21 other study(ies) available for erlotinib hydrochloride and Angiogenesis, Pathologic
| Article | Year |
|---|---|
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Topics: A549 Cells; Acrylamides; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Crizotinib; Drug Synergism; Erlotinib Hydrochloride; Female; Genes, erbB-1; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Oncogenes; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Ramucirumab; Random Allocation; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
Topics: Animals; Aptamers, Nucleotide; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Integrin alphaVbeta3; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NIH 3T3 Cells; Protein Binding; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.
Topics: Animals; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mutation; Neovascularization, Pathologic; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; MAP Kinase Signaling System; Melanoma; Membrane Glycoproteins; Neoplasm Invasiveness; Neovascularization, Pathologic; Up-Regulation | 2019 |
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
Topics: Animals; Apoptosis; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oncolytic Virotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Simplexvirus; Survival Rate; Tumor Cells, Cultured; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays | 2014 |
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A | 2014 |
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique, Indirect; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Quinazolines | 2015 |
Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Hypoxia; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Reproducibility of Results; Transcriptome; Treatment Outcome | 2015 |
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2015 |
Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents; Cell Proliferation; Cone-Beam Computed Tomography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, p53; Genes, ras; Lung Neoplasms; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; Quinazolines; Tumor Burden | 2009 |
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured | 2009 |
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand | 2012 |
A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines | 2012 |
Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Becaplermin; Cell Division; Cyclooxygenase 2; Cytokines; Drug Evaluation, Preclinical; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred DBA; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Quinazolines; Synovial Membrane | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides | 2012 |
Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Intravitreal Injections; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Oxygen; Protein Kinase Inhibitors; Quinazolines; Retinal Diseases; Signal Transduction; Tissue Inhibitor of Metalloproteinase-3 | 2013 |
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
Topics: Animals; Cell Line; Cell Line, Tumor; Cells, Cultured; Chlorocebus aethiops; ErbB Receptors; Erlotinib Hydrochloride; Genetic Therapy; Humans; Immunoblotting; In Situ Hybridization; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Nerve Sheath Neoplasms; Oligonucleotide Array Sequence Analysis; Oncolytic Virotherapy; Protein Kinase Inhibitors; Quinazolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Simplexvirus; Vero Cells; Xenograft Model Antitumor Assays | 2007 |
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |